AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25932481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service usage
Number of subjects: 236
Study 22898749 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential moments group (G1) with a nickel titanium (NiTi) intrusion arch and a 150g NiTi closing coil spring for canine retraction.
Number of subjects: 28
Study 22898749 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary anchorage devices (TAD) group (G2) with one miniscrew placed between maxillary second premolars and first molars and a 150g NiTi closing coil spring.
Number of subjects: 28
Study 22898749 — intervention group
Group type: COMPARATOR
Intervention: Both groups (G1 and G2)
Number of subjects: 28
Study 22898749 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD group (G2)
Number of subjects: 28
Study 21737486 — intervention group
Group type: EXPERIMENTAL
Intervention: FDTV 180 mg + T 2 mg, once a day
Number of subjects: 40
Study 21737486 — intervention group
Group type: COMPARATOR
Intervention: T 2 mg once a day
Number of subjects: 40
Study 18688627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis major myocutaneous flap with adjuvant radiotherapy
Number of subjects: 7
Study 18688627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 7
Study 16520326 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 MHz GSM mobile phone signal
Number of subjects: 120
Study 16520326 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐pulsing carrier wave signal
Number of subjects: 120
Study 16520326 — intervention group
Group type: COMPARATOR
Intervention: sham condition with no signal present
Number of subjects: 120
Study 15254051 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA continuous (10 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0
Study 15254051 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA cyclical (10 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0
Study 15254051 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MP (200 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0
Study 15254051 — intervention group
Group type: COMPARATOR
Intervention: CEE (0.625 mg/d)
Number of subjects: 0
Study 11177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray, 200 microg once daily
Number of subjects: 75
Study 11177038 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 75
Study 9193210 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Number of subjects: 19
Study 9193210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1548520 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and MeCCNU
Number of subjects: 210
Study 1548520 — intervention group
Group type: COMPARATOR
Intervention: Escalating 5-FU
Number of subjects: 210
Study 2992562 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (20 mg)
Number of subjects: 0
Study 2992562 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (50 mg)
Number of subjects: 0
Study 2992562 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (all doses)
Number of subjects: 0
Study 2992562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31615196 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based physical and cognitive training
Number of subjects: 34
Study 31615196 — intervention group
Group type: COMPARATOR
Intervention: Combined physical and cognitive training (CPC)
Number of subjects: 34
Study 30174421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 159
Study 30174421 — intervention group
Group type: COMPARATOR
Intervention: Diskus + HandiHaler
Number of subjects: 159
Study 30174421 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler + HandiHaler
Number of subjects: 159
Study 25933674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Aerobics (MA) training
Number of subjects: 47
Study 25933674 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 47
Study 25377592 — intervention group
Group type: EXPERIMENTAL
Intervention: FTMB (0.5, 1.5, 3.0, or 6.0 mg/kg)
Number of subjects: 118
Study 25377592 — intervention group
Group type: COMPARATOR
Intervention: Herceptin(®) (6 mg/kg)
Number of subjects: 118
Study 25377592 — intervention group
Group type: EXPERIMENTAL
Intervention: FTMB (Test)
Number of subjects: 118
Study 25377592 — intervention group
Group type: EXPERIMENTAL
Intervention: FTMB
Number of subjects: 118
Study 25377592 — intervention group
Group type: COMPARATOR
Intervention: Herceptin(®)
Number of subjects: 118
Study 22548384 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcD > 60 ms
Number of subjects: 53
Study 22548384 — intervention group
Group type: COMPARATOR
Intervention: QTcD ≤ 60 ms
Number of subjects: 53
Study 20626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment protocol including bilateral use of acupoints (Fengchi (GB20), Taiyang (EX‐HN5), etc.), manual stimulation, 30 minutes per session, 20 needles per session, total duration of at least 10 weeks, treatment frequency of twice a week with one week rest between the first 10 and last 10 sessions.
Number of subjects: 0
Study 19192475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 742
Study 19192475 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 742
Study 16259861 — intervention group
Group type: EXPERIMENTAL
Intervention: Software system for randomised database study
Number of subjects: 0
Study 16259861 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised database study approach
Number of subjects: 0
Study 12182290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid connection
Number of subjects: 30
Study 12182290 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rigid connection
Number of subjects: 30
Study 12182290 — intervention group
Group type: COMPARATOR
Intervention: Control (rigid vs non-rigid)
Number of subjects: 30
Study 10548704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (200 mg)
Number of subjects: 41
Study 10548704 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.2 mg)
Number of subjects: 41
Study 7789345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary group
Number of subjects: 61
Study 7789345 — intervention group
Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 61
Study 7789345 — intervention group
Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 61
Study 7789345 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study 1698039 — intervention group
Group type: COMPARATOR
Intervention: Pentamorphone 0.60 micrograms/kg, IV
Number of subjects: 12
Study 1698039 — intervention group
Group type: COMPARATOR
Intervention: Pentamorphone 0.24 micrograms/kg, IV
Number of subjects: 12
Study 1698039 — intervention group
Group type: COMPARATOR
Intervention: Pentamorphone 0.08 micrograms/kg, IV
Number of subjects: 12
Study 1698039 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study 378632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine
Number of subjects: 69
Study 378632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 7167311 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant walker, used for a minimum of 1 hr. per day from 4 months of age until the onset of bipedal locomotion.
Number of subjects: 30
Study 7167311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infant walker).
Number of subjects: 30
Study 30448246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) injections
Number of subjects: 43
Study 30448246 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TAC) injections
Number of subjects: 43
Study 30566004 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg or maximum tolerated dose)
Number of subjects: 9340
Study 30566004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 26743240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg/day, n = 21)
Number of subjects: 40
Study 26743240 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (0.3-0.9 mg/day, n = 19)
Number of subjects: 40
Study 25108586 — intervention group
Group type: EXPERIMENTAL
Intervention: iv-B (intravenous oxytocin when anterior shoulder seen)
Number of subjects: 600
Study 25108586 — intervention group
Group type: COMPARATOR
Intervention: iv-A (intravenous oxytocin after delivery of the fetus)
Number of subjects: 600
Study 25108586 — intervention group
Group type: COMPARATOR
Intervention: im-A (intramuscular oxytocin after delivery)
Number of subjects: 600
Study 25108586 — intervention group
Group type: COMPARATOR
Intervention: im-B (intramuscular oxytocin when anterior shoulder seen)
Number of subjects: 600
Study 21833852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 456
Study 21833852 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 456
Study 21833852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ultrasonography and physical examination
Number of subjects: 456
Study 20130093 — intervention group
Group type: EXPERIMENTAL
Intervention: 8400 IU vitamin D(3)
Number of subjects: 226
Study 20130093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 17324825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of epinastine hydrochloride
Number of subjects: 79
Study 17324825 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of chlorpheniramine maleate
Number of subjects: 79
Study 15749044 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant av-fistula
Number of subjects: 50
Study 15749044 — intervention group
Group type: COMPARATOR
Intervention: control group (without av-fistula)
Number of subjects: 50
Study 12002490 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐V Impulse foot pump
Number of subjects: 229
Study 12002490 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 229
Study 10388229 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected colonic segment showing cobblestone appearance characteristic of Crohn's disease
Number of subjects: 92
Study 10388229 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of resected colonic segment
Number of subjects: 92
Study 7890211 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Isosorbide-5-mononitrate (Is-5-Mn)
Number of subjects: 25
Study 7890211 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Isosorbide-5-mononitrate (Is-5-Mn)
Number of subjects: 25
Study 2197583 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative controlled infusion of 10 mg Propionibacterium avidum KP‐40
Number of subjects: 68
Study 2197583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 68
Study 656269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (0.5-2 mg)
Number of subjects: 0
Study 656269 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (dose not specified)
Number of subjects: 0
Study 656269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide and Frusemide (high dosage in renal failure)
Number of subjects: 0
Study 30580577 — intervention group
Group type: EXPERIMENTAL
Intervention: High survey response rates
Number of subjects: 12000
Study 30580577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit of high response rates
Number of subjects: 12000
Study 30580577 — intervention group
Group type: EXPERIMENTAL
Intervention: Costly pursuit of high response rates
Number of subjects: 12000
Study 29158206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with balance training
Number of subjects: 400
Study 29158206 — intervention group
Group type: COMPARATOR
Intervention: Usual pulmonary rehabilitation (control)
Number of subjects: 400
Study 25671798 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus endovascular treatment with thrombectomy devices
Number of subjects: 316
Study 25671798 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 316
Study 22308561 — intervention group
Group type: EXPERIMENTAL
Intervention: R&R2 ADHD program (group condition)
Number of subjects: 31
Study 22308561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (waiting-list control)
Number of subjects: 31
Study 21642681 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with CA‐125 for 6 years and transvaginal ultrasound for 4 years
Number of subjects: 78126
Study 21642681 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78126
Study 21642681 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with CA‐125 and transvaginal ultrasound
Number of subjects: 78126
Study 19178404 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT)
Number of subjects: 41
Study 19178404 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 41
Study 19178404 — intervention group
Group type: COMPARATOR
Intervention: Skin tests (Group I)
Number of subjects: 41
Study 19178404 — intervention group
Group type: COMPARATOR
Intervention: Skin tests (Group II)
Number of subjects: 41
Study 19178404 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin hapten
Number of subjects: 41
Study 17420953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 19
Study 17420953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15134106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with foldable IOL implantation
Number of subjects: 68
Study 15134106 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-surgery measurements)
Number of subjects: 68
Study 11079280 — intervention group
Group type: COMPARATOR
Intervention: Oral ondansetron 16 mg plus dexamethasone 12 mg
Number of subjects: 61
Study 11079280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron 1 mg plus dexamethasone 12 mg
Number of subjects: 61
Study 9148022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dra I RFLP polymorphism
Number of subjects: 319
Study 9148022 — intervention group
Group type: EXPERIMENTAL
Intervention: Msp I, Pst I, and Rsa I RFLPs
Number of subjects: 319
Study 9148022 — intervention group
Group type: COMPARATOR
Intervention: Comparison of different genotypes among moderate alcohol consumers (n = 43) or chronic alcoholics (n = 243)
Number of subjects: 319
Study 9148022 — intervention group
Group type: COMPARATOR
Intervention: Allelic frequencies for each RFLP
Number of subjects: 319
Study 8363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia with tramadol/metamizol (max. tramadol 400 mg+metamizol 5 g in any 24 h) after major surgery and additional administration of piritramide as needed (max. 60 mg/24 h.i.v.)
Number of subjects: 168
Study 8363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 500 mg) after minor surgery
Number of subjects: 168
Study 8363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment using VAS, VRS, MPQ, and SFMPQ
Number of subjects: 168
Study 3012072 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a single 1-g marihuana cigarette containing 1.8% delta 9-tetrahydrocannabinol
Number of subjects: 0
Study 3012072 — intervention group
Group type: COMPARATOR
Intervention: Marihuana placebo cigarette smoking
Number of subjects: 0
Study 31366458 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 0
Study 31366458 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment
Number of subjects: 0
Study 31366458 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness as a marker
Number of subjects: 0
Study 28173960 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 84496
Study 25420618 — intervention group
Group type: EXPERIMENTAL
Intervention: Included condition
Number of subjects: 138
Study 25420618 — intervention group
Group type: COMPARATOR
Intervention: Excluded condition
Number of subjects: 138
Study 23803334 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 182
Study 23803334 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 182
Study 21784445 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176
Study 21784445 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 176
Study 21784445 — intervention group
Group type: COMPARATOR
Intervention: Term-born children (comparison group)
Number of subjects: 176
Study 19331486 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (received $5 for each of the 15 consent items they could answer correctly)
Number of subjects: 31
Study 19331486 — intervention group
Group type: COMPARATOR
Intervention: Control group (received standard informed consent procedure)
Number of subjects: 31
Study 17042168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction (OHI) alone
Number of subjects: 10
Study 17042168 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and metronidazole dental gel
Number of subjects: 10
Study 17042168 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and subgingival scaling
Number of subjects: 10
Study 17042168 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and subgingival scaling plus metronidazole gel
Number of subjects: 10
Study 15055564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 575
Study 15055564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg
Number of subjects: 575
Study 15055564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 10823100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40
Study 10823100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40
Study 10823100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40
Study 10823100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8801192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg twice daily for two weeks)
Number of subjects: 32
Study 8801192 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented patients)
Number of subjects: 32
Study 8801192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 32
Study 1377455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 1 mg/kg i.v.
Number of subjects: 24
Study 1377455 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms/kg i.v.
Number of subjects: 24
Study 6502663 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar method on clinical teaching
Number of subjects: 46
Study 31758610 — intervention group
Group type: EXPERIMENTAL
Intervention: UCC118 supplementation
Number of subjects: 7
Study 31758610 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 7
Study 30235384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Epidermal Growth Factor (EGF) serum applied twice daily for eight weeks
Number of subjects: 15
Study 30235384 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for eight weeks
Number of subjects: 15
Study 30235384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Epidermal Growth Factor (EGF) serum
Number of subjects: 15
Study 27785516 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 150
Study 27785516 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 150
Study 24534613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing
Number of subjects: 125
Study 24534613 — intervention group
Group type: COMPARATOR
Intervention: Non-drawing (Control)
Number of subjects: 125
Study 23135337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 117
Study 23135337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 117
Study 23135337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21187353 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 0
Study 21187353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17911617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with recombinant Bet v 1 derivatives
Number of subjects: 0
Study 17911617 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimer recombinant Bet v 1
Number of subjects: 0
Study 17911617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragments of recombinant Bet v 1
Number of subjects: 0
Study 17911617 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone
Number of subjects: 0
Study 16061314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve decompression without transposition
Number of subjects: 66
Study 16061314 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous anterior transposition of the nerve
Number of subjects: 66
Study 12198065 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg IM phenylephrine
Number of subjects: 90
Study 12198065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg IM phenylephrine
Number of subjects: 90
Study 12198065 — intervention group
Group type: COMPARATOR
Intervention: Saline (N/C group)
Number of subjects: 90
Study 12198065 — intervention group
Group type: COMPARATOR
Intervention: Saline (H/C group)
Number of subjects: 90
Study 9989959 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated heparin control system (AutoHep) with initial bolus of heparin
Number of subjects: 12
Study 9989959 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated heparin control system (AutoHep) without initial bolus of heparin
Number of subjects: 12
Study 9989959 — intervention group
Group type: COMPARATOR
Intervention: Control (current clinical practice)
Number of subjects: 12
Study 9989959 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood sampling system
Number of subjects: 12